AbbVie Announced That The U.S. FDA Has Approved EPKINLY As The First And Only T-cell Engaging Bispecific Antibody Administered Subcutaneously For The Treatment Of Adults With Relapsed Or Refractory Follicular Lymphoma
AbbVie Announced That The U.S. FDA Has Approved EPKINLY As The First And Only T-cell Engaging Bispecific Antibody Administered Subcutaneously For The Treatment Of Adults With Relapsed Or Refractory Follicular Lymphoma
艾伯維公司宣佈，美國FDA已批准EPKINLY作爲首個並且唯一能皮下給藥的T細胞結合雙特異性抗體，用於治療復發或難治性濾泡性淋巴瘤的成年患者。
AbbVie Announced That The U.S. FDA Has Approved EPKINLY As The First And Only T-cell Engaging Bispecific Antibody Administered Subcutaneously For The Treatment Of Adults With Relapsed Or Refractory Follicular Lymphoma
艾伯維公司宣佈，美國FDA已批准EPKINLY作爲首個並且唯一能皮下給藥的T細胞結合雙特異性抗體，用於治療復發或難治性濾泡性淋巴瘤的成年患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。